Peak Pharmaceuticals (OTCMKTS:PKPH – Get Free Report) and Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.
Analyst Ratings
This is a breakdown of current ratings and price targets for Peak Pharmaceuticals and Cyclacel Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Peak Pharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
| Cyclacel Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Insider and Institutional Ownership
23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 18.4% of Peak Pharmaceuticals shares are owned by company insiders. Comparatively, 23.7% of Cyclacel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Peak Pharmaceuticals | N/A | N/A | -$160,000.00 | N/A | N/A |
| Cyclacel Pharmaceuticals | $750,000.00 | 6.48 | -$3.00 million | ($4.54) | -0.19 |
Peak Pharmaceuticals has higher earnings, but lower revenue than Cyclacel Pharmaceuticals.
Risk and Volatility
Peak Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.38, suggesting that its share price is 138% less volatile than the S&P 500.
Profitability
This table compares Peak Pharmaceuticals and Cyclacel Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Peak Pharmaceuticals | N/A | N/A | -159.55% |
| Cyclacel Pharmaceuticals | N/A | -51.21% | -44.00% |
Summary
Cyclacel Pharmaceuticals beats Peak Pharmaceuticals on 5 of the 8 factors compared between the two stocks.
About Peak Pharmaceuticals
Peak Pharmaceuticals, Inc. manufactures and markets pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of industrial hemp for the prevention and alleviation of various conditions and diseases. The company was founded on December 18, 2007 and is headquartered in Scottsdale, AZ.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Receive News & Ratings for Peak Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peak Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
